New drug trial aims to slow scarring in lungs
NCT ID NCT07447102
Summary
This study is testing an investigational drug called BC006 in people with idiopathic pulmonary fibrosis (IPF), a serious lung scarring disease. Over 24 weeks, researchers will compare BC006 against a placebo in 96 participants to see if it can help slow the decline in lung function. The main goal is to measure changes in breathing capacity and check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.